Fanatics Collectibles to Open Its First-Ever Global Flagship Store in the Spring of 2025, to Be Located on Iconic Regent Street in London
22.1.2025 13:00:00 CET | Business Wire | Press release
The Much-Anticipated Interactive Store Will Focus on Sports and Entertainment Trading Cards, Offer Exclusive Product and Host Events, Athletes and ClubsIncluded in Its Unique Footprint: An In-Store Breaking Area, a State-of-the-Art Trading-Card Singles Experience, Card Opening and Trading Areas and Customer Education Touchpoints
Today Fanatics Collectibles announced its first-ever flagship store, to open in the spring of 2025 on iconic Regent Street in London. The focus: sports and entertainment trading cards and trading-card games, featuring Fanatics Collectibles’ brands, including Topps, Merlin, Match Attax and Bowman. Last year Topps secured the exclusive trading-card rights to the Premier League, with product launching in time for the 2025/2026 season. Topps also currently has the exclusive rights for UEFA national team competitions and club competitions and will begin making licensed NBA product later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122281845/en/
(Photo: Fanatics Collectibles)
The much-anticipated store will span 803 square meters (8,647 square feet), and give collectors a one-of-a-kind experience seven days a week. The stunning visual centerpiece: a central display of the rarest and most-desirable cards, all with a giant suspended circular screen above. The flagship will offer exclusive product and have thousands of unique items, inclusive of single cards, retail boxes and high-end hobby releases. It will also see highly trafficked community-building events from monthly trade nights, kids rip events, athlete signings and appearances, partner activations and grading drop-off. Along with retail space, the store will feature a state-of-the-art breaking studio (live and taped opening of card packs), interactive customer education touchpoints – and a personal card creation suite.
“We are incredibly excited to cut the ribbon on this amazing community-building retail space, one that we hope will delight collectors and be a true home for the hobby in Europe,” said Topps President of Trading Cards, David Leiner. “It’ll be a destination for millions of fans as well as our own internal partners – and team and club partners, the latter using our dedicated space to launch and showcase new products in a way that has never been done before.” Speaking to internal partners, the new store will serve as a drop-off point for users of Fanatics Collect, a dynamic marketplace that connects buyers and sellers of trading cards. To the flagship being a home for fans and collectors, currently there are less than five Topps-partner hobby shops in the UK, and less than 30 in all of Europe. The annual footfall of south Regent Street is more than 70 million people.
While the store will focus primarily on trading cards, other items will be sold, including apparel (both Topps-branded and Fanatics-owned Mitchell & Ness) and memorabilia (signed kits, jerseys, balls and other equipment) and trading-card supplies. Types of trading-card products in the store: sports (soccer, football, baseball, F1, basketball, UFC, WWE), sports gaming cards (Match Attax) and entertainment (Disney, Marvel, Star Wars, Pixar, Garbage Pail Kids, Stranger Things).
About Fanatics Collectibles
Fanatics Collectibles is a new model and vision for the hobby fundamentally changing the experience for current and future collectors, leagues, and players across many professional and college sports. The organization secured long-term, exclusive rights to design, manufacture and distribute trading cards for several sports and entertainment properties, including MLB, MLBPA, the Premier League, MLS, UFC, Formula 1 as well as Disney, Marvel, Pixar and Star Wars, among others. In January 2022, Fanatics Collectibles announced the acquisition of Topps, establishing the preeminent licensed trading card brand as the cornerstone of Fanatics’ trading cards and collectibles business and jumpstarted its MLB and MLBPA rights to design, manufacture and distribute trading cards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122281845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom